Drug profile · INN
dostarlimab
JEMPERLI
dostarlimab (JEMPERLI) is a programmed cell death protein 1 antagonist. Associated with GlaxoSmithKline.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01FF07
Patents linked 0
Pipeline programs 26
News articles 0
Drug details — dostarlimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 26
- Data quality
- 0.83
Quick answer
dostarlimab (JEMPERLI) is a programmed cell death protein 1 antagonist. Associated with GlaxoSmithKline.
Key facts
INN dostarlimab
Brand JEMPERLI
Mechanism Programmed cell death protein 1 antagonist
Target Programmed cell death protein 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FF07
Originator GlaxoSmithKline
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dostarlimab?
dostarlimab (JEMPERLI) is a programmed cell death protein 1 antagonist. Associated with GlaxoSmithKline.
What is the brand name for dostarlimab?
JEMPERLI is a marketed brand name for dostarlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.